In this week’s issue:
Announcement: Please see the attached email from the Office of the Vice-President Research & International regarding upcoming award opportunities
- The Leukemia & Lymphoma Society – The New Idea Award
- 2012/13 Program on Research and Innovation Leading to Rapid Detection of Pathogenic E. Coli
- Prostate Cancer Foundation – PCF 2013 Young Investigator Awards
- Autism Speaks – Treatment Research RFA for 2013
- CIHR Open Operating Grant: 2013 (Reminder)
Honours and Awards:
- Alfred Taubman Medical Research Institute – Taubman Prize for Translational Medical Science
- LifeSciences British Columbia – The Faces of Innovation – Call for Nominations
- Faculty of Medicine – Leaders in Medical Discovery
Deadline: January 3, 2013
The Leukemia & Lymphoma Society is proud to announce THE NEW IDEA AWARD, a new grant program to develop safer and more effective treatment paradigms for patients with hematological malignancies. Specifically, this program represents a concept grant to support academic researchers with innovative therapy ideas that are substantially different from current standard treatments and may advance to clinical testing in the short-term.
The goal of this RFA is to evaluate novel concepts that could lead to significant improvements in the clinical outcomes, including quality of life, of patients with hematological malignancies. Grants will support initial exploration of untested but potentially transformative research ideas and treatment approaches. In order to receive such an award, applicants must succinctly describe the innovative idea/approach and a method for testing it within the one year grant period.
Upon completion of the one year period, applicants will be evaluated on the extent to which their concept has been substantiated by initial testing, and promising projects may be selected for extended funding. The overall goal of THE NEW IDEA AWARD program is to deliver novel treatments and ultimately cures for more patients with hematological malignancies.
Grants will be awarded in an amount of up to $100,000 for a one-year grant period. Depending on the response and quality of the proposals, there may be up to 8 awards.
LOI Deadline: January 14, 2013 A new funding program has been launched by a consortium of Canadian research organizations to fund development of an innovative test for detecting the presence of pathogenic E. coli bacteria during food production. This program, titled “2012/13 Program on Research and Innovation Leading to Rapid Detection of Pathogenic E. Coli”, aims to foster continuous improvement in the safety of the Canadian food supply and create long-term health benefits for Canada.
A total of $1.025 million is available over 18 months for one or two projects to develop a genomic-based detection methodology that is rapid, sensitive, specific, affordable and field-deployable. The funding partners include: Alberta Innovates Bio Solutions ($250,000), Genome Alberta on behalf of ALMA ($500,000), Genome Canada ($250,000) and additional support from the Ontario Ministry of Agriculture, Food and Rural Affairs.
While an investigator associated with a Canadian academic institution will lead or co-lead the project, the team may tap into the best expertise globally and engage scientists within academic institutions, provincial or federal research centres, private industry or non-profit research establishments.
The deadline for submission of a letter of intent (LOI) is January 14, 2013, 2:00 p.m. MST. Forms and additional information are available at www.genomealberta.ca.
Deadline: February 1, 2013
The Prostate Cancer Foundation is pleased to announce a new round of funding for Prostate Cancer Researchers. Consistent with our goal to end death and suffering from prostate cancer, we would like to focus efforts on developing another gifted cohort of human capital in prostate cancer research. Highly innovative basic science programs will be carefully considered, but priority will be given to “bench to bedside” translational research proposals with the potential to deliver near term benefit to patients.
PCF Young Investigator awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used flexibly to advance the career and research efforts of the awardee. We welcome applications from the global community. Applicants need not be trained specifically in clinical prostate cancer research. Young Investigators may be working in basic, translational, clinical, population sciences, bioengineering or any other field that could contribute to the end of prostate cancer. However, successful applicants should be working in a research environment capable of supporting transformational prostate cancer research. Access to and interaction with a clinical environment, as well as translational prostate cancer physician-scientists, is highly desirable. This year we wish to extend a special invitation to RESEARCH MOLECULAR PATHOLOGISTS and BIOINFORMATICIANS to apply for this award.
Deadline: February 21, 2013
Autism Speaks invites both Full- and Pilot-Level Treatment research grant applications to conduct innovative clinical studies of novel interventions for individuals with Autism Spectrum Disorders (ASD) throughout the lifespan. These may include medical approaches including complementary and alternative forms of health care and pharmacological treatments, as well as behavioral and/or psychosocial interventions, and evaluation of the efficacy, safety or therapeutic benefits of all types of interventions. Also appropriate are animal model studies that test the effects of novel compounds for reducing autism symptoms. Please read the RFA at the link above for complete details.
Registration Deadline: February 1, 2013
Application Deadline: March 1, 2013
The CIHR Open Operating Grant Program (OOGP) provides operating funds to support research proposals in all areas of health research including randomized controlled trials. A randomized controlled trial (RCT) is an experiment in which investigators randomly assign eligible human research participants or other units of study (e.g., classrooms, clinics, playgrounds) into groups to receive or not receive one or more interventions that are being compared. The results are analyzed by comparing outcomes in the groups.
The OOGP is the largest of the open calls for proposals within CIHR’s programming. CIHR recognizes that the creativity, skill, and insight of individuals and self-assembled teams lie at the heart of the research enterprise. The pursuit of excellence in research, as evaluated through the peer review process, inspires ideas that drive progress and ensures a continuous flow of fresh insights. Through the OOGP, CIHR aims to fund the best ideas in Canadian health research today.
HONOURS AND AWARDS
Deadline: January 1, 2013
In October, the A. Alfred Taubman Medical Research Institute at the University of Michigan awarded the first annual $100,000 Taubman Prize for Translational Medical Science to Dr. Harry (Hal) Dietz, a geneticist and cardiologist at Johns Hopkins University, for his transformative work in the study and treatment of Marfan syndrome and related disorders.
The prize was established last year to recognize the clinician-scientist who is making the most significant contribution to translating basic research findings into medical practice. The 2013 winner will receive the prize and serve as the keynote speaker at the Taubman Institute’s annual symposium, which is scheduled for Friday, Oct. 11, in Ann Arbor, MI.
The deadline for entries for the 2013 award is Jan. 1. We would be grateful if you would inform your faculty members of the opportunity offered by the Taubman Prize to reward great work in translational research. All clinician-scientists, regardless of country, are eligible, excluding U-M researchers.
A panel of prominent clinician-scientists will judge nominees based on their contribution to translating basic research findings into clinical applications and by the manner in which their clinical practice connects to their research.
Contest rules and nomination forms can be found at the website link above.
Deadline: January 25, 2013
The Faces of Innovation is a celebration of 15 years of the LifeSciences British Columbia Awards, recognizing the leaders in our community who have transformed the life sciences sector as we know it while looking towards the leaders of tomorrow who will set the stage for the next 15 years of growth and success.
We invite all members of B.C.’s life sciences community to nominate individuals or companies for the 2013 LifeSciences British Columbia Awards. LifeSciences BC proudly hosts this annual event which has become the premier celebration for the life sciences community each year. Please submit a nomination and join us in celebrating The Faces of Innovation.
Both LifeSciences BC members and non-members may nominate either companies or individuals using the criteria outlined below. Awards may be given in any of the life sciences sectors represented by LifeSciences BC including but not limited to: biopharmaceutical, medical device, medical technology, health IT and genomics.
Please see the attached call for nominations for more information.
Faculty of Medicine – Leaders in Medical Discovery
Date: January 16, 2013 9:30am
Jan Friedman, Professor in the Department of Medical Genetics and David Speert, Professor in the Department of Pediatrics, both members of the Child & Family Research Institute, have received the Distinguished Medical Research Lecturer Awards from the Faculty of Medicine for 2012. Acceptance of this award is accompanied by a guest seminar open to all faculty members and students as part of the “Leaders in Medical Discovery” Series.
Research Secretary | Faculty of Medicine | Dean’s Office | Research
The University of British Columbia | 317-2194 Health Sciences Mall | Vancouver BC V6T 1Z3
Phone (604) 822-8633 | Fax (604) 822-6061